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3,4-Methylenedioxymethamphetamine (MDMA) is associated with changes in
neurocognitive performance. Recent studies in laboratory animals have provided
additional support for the neurodegeneration hypothesis. However, results from animal
research need to be applied to humans with caution. Moreover, several of the studies
that examine MDMA users suffer from methodological shortcomings. Therefore,
a prospective cohort study was designed in order to overcome these previous
methodological shortcomings and to assess the relationship between the continuing
use of MDMA and cognitive performance in incipient MDMA users. It was hypothesized
that, depending on the amount of MDMA taken, the continued use of MDMA over
a 2-year period would lead to further decreases in cognitive performance, especially
in visual paired association learning tasks. Ninety-six subjects were assessed, at the
second follow-up assessment: 31 of these were non-users, 55 moderate-users, and
10 heavy-users. Separate repeated measures analyses of variance were conducted for
each cognitive domain, including attention and information processing speed, episodic
memory, and executive functioning. Furthermore, possible confounders including age,
general intelligence, cannabis use, alcohol use, use of other concomitant substances,
recent medical treatment, participation in sports, level of nutrition, sleep patterns, and
subjective well-being were assessed. The Repeated measures analysis of variance
(rANOVA) revealed that a marginally significant change in immediate and delayed
recall test performances of visual paired associates learning had taken place within
the follow-up period of 2 years. No further deterioration in continuing MDMA-users
was observed in the second follow-up period. No significant differences with the
other neuropsychological tests were noted. It seems that MDMA use can impair visual
paired associates learning in new users. However, the groups differed in their use of
concomitant use of illicit drugs. Therefore, performance differences between the groups
cannot completely ascribed to the use of MDMA.
Keywords: MDMA, cognition, verbal memory
INTRODUCTION
3,4-Methylenedioxymethamphetamine (MDMA) is a psychostimulant drug which is commonly
referred to as “ecstasy.” MDMA has historically been linked to the electronic dance-music scene,
and its use is concentrated among young adults, especially young males. Although, a decline in the
popularity of ecstasy was recorded for the years, 2005–2010, the data from 2011 shows that this
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decrease appears to have been temporary, with a new increase in
ecstasy use in some countries1. In 2012, the prevalence of ecstasy
use in the 15–34-year-old population was 0.6–12.4% in Europe,
with the highest prevalence in the United Kingdom (12.4%)
and the Netherlands (11.6%)2. In North America the prevalence
of ecstasy use is even higher than in Europe (U.N.O.o.D.a.C
(UNODC), 2013).
A plethora of studies concerning the neurotoxic effects of
MDMA in animals and humans supports the neurodegeneration
hypothesis with evidence for selective damage to serotonergic
axon terminals in the central nervous system (CNS) in
laboratory animals, (Parrott, 2013a). Different investigators
found impairments in non-spatial, spatial and reference-memory
performance tasks in rats after the administration of MDMA
(Camarasa et al., 2008; Arias-Cavieres et al., 2010; Kay et al., 2010;
McAleer et al., 2013). Interestingly, due to the administration of
Memantine, impairments in memory and learning performances
due to MDMA seemed to be reversible in rats (Camarasa
et al., 2008). However, the findings from animal research can
only be applied to humans with caution (Green et al., 2012).
Factors like the administration of MDMA, its bioavailability,
concentration-dose relationships, possible active metabolites and
concentration, as well as dependent plasma protein bindings
differ among species and this can affect the pharmacokinetics and
pharmacodynamics of MDMA (Green et al., 2012). Nevertheless,
extensive empirical evidence exists that shows the negative effects
ofMDMAon humans, including a reduction in serotonin (5-HT)
markers in the CNS (Parrott, 2013a).
The most consistently reported impairments among
former and current MDMA users with regard to serotonergic
dysfunction include altered executive functioning, as well
changes in psychological well-being, neuroendocrine secretion,
vegetative functions, the processing of sensory stimuli, sleep
architecture, and cognition. However, in most studies deficits
in memory were also demonstrated (Parrott, 2013a). Even
abstinent MDMA-users seem to have dose-related impairments
in delayed visual and immediate verbal memory performances
(Bolla et al., 1998). These deficits are linked, among other factors,
to the altered serotonergic fiber density in the hippocampus,
which is crucial for the processes of learning—and especially
vulnerable to the neurotoxic effects of MDMA (Hatzidimitriou
et al., 1999; Daumann et al., 2005; Brown et al., 2010; Pergola
and Suchan, 2013). Because of the neurotoxic effect of MDMA
on the serotonergic fiber density in the hippocampus, many
investigations have found deficits in associative learning with
poorer immediate and delayed recall abilities in MDMA users
compared to non-users (Parrott et al., 1998; Montgomery et al.,
2005). Furthermore, those findings were not only demonstrated
in heavy MDMA users but also in new MDMA-users after low
doses of MDMA use within a short period of lifetime use (Schilt
et al., 2007; Wagner et al., 2013).
However, many of the research studies that have examined
MDMA users suffered from several methodological problems
1UNODC, World Drug Report 2013 (United Nations publication, Sales No.
E.13.XI.6).
2UNODC, World Drug Report 2012 (United Nations publication, Sales No.
E.12.XI.1).
(e.g., pre-existing differences, polydrug use, differences in
lifestyle). In order to account for these shortcomings, we
conducted a prospective study. The first results of the current
study after a 1-year follow-up period have already been published,
(Wagner et al., 2013). In this study, a number of possible
interfering variables were explored and taken into account during
the analysis of the results (Wagner et al., 2013). Significant effects
of immediate and delayed recall of visual paired association
learning tasks between MDMA users and controls were found.
The authors concluded that MDMA appears to impair visual
paired association learning in new users, suggesting serotonergic
dysfunction in hippocampal regions as a consequence of MDMA
use. In the meantime it has been possible to evaluate the
corresponding data from the 2-year follow-up assessment. As
with the previous study, the aim of this study was to address the
following question: Does the use of MDMA over a period of 2
years lead to changes in cognitive performance with regard to any
of the neurocognitive tests?
With respect to the previous findings from the first follow-up
assessment, we expect, depending upon the amount of MDMA
that was taken, that the continued use of MDMA over a 2-year
period will lead to further decreases in cognitive performance,
especially in visual paired association learning tasks.
METHODS
Participants
Hundred and forty-nine new MDMA users with no current
physical disorders and no current or previous history of
neurological or psychiatric disorders (Axis I and II according
to DSM-IV criteria; American Psychiatric Association, 1994)
were included in the study. Further exclusion criteria were the
following: ingestion of any other illicit psychotropic substances
besides cannabis on more than five occasions before the day
of the first examination; a history of alcohol misuse (according
to DSM-IV criteria, American Psychiatric Association, 1994);
and regular medication (except for contraceptives). The main
inclusion criterion for the baseline was a high probability of
future ecstasy use, operationalized as having some but very
limited experience with MDMA (maximum of five pills). The
study was carried out between 2006 and 2011 at the department
of psychiatry and psychotherapy of the University of Cologne.
The participants were invited back after 12 and 24 months. Of
the initial 109 subjects present during the second assessment (t1),
96 subjects [63 males, 33 females; age range: 18–41 years, mean
age: 22.99 years, standard deviation (SD): 4.529] participated in
the third assessment (t2). In order to rule out acute intoxication
effects, the participants were abstaining from cannabis on both
study days during which the cognitive assessment was carried
out. It would have been implausible to recruit MDMA users
with a longer period of abstinence given the fact that most
MDMA users also use cannabis on a regular basis (Parrott
et al., 2007). Furthermore, participants had to be abstinent from
any other illicit substances for at least seven (7) days in order
to rule out acute intoxication effects. Subjects were recruited
by placing advertisements in magazines and newspapers and
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via notifications posted on campus. The study was part of a
larger investigation including psychopathological and neuro-
imaging measures that will be submitted elsewhere. The study
was approved by the Ethics Committee of the Medical Faculty
of the University of Cologne in Germany.
Procedure
All participants were asked to give written informed consent
prior to the cognitive assessment. This was followed by a
structured interview that, was designed to assess the use of
illicit psychotropic substances. For all prevalent psychotropic
substances, the interview included questions concerning the
participants’ age at first use, the number of days since their last
use, the average and maximal frequency of their use measured
in days per month, their estimated cumulative lifetime dose,
their average daily dose, the highest daily dose they had ever
used and the duration of their regular use measured in months.
For the second and third assessments, the interview covered
the following criteria: their age of first use (only assessed if the
relevant substance had not been used before), the number of
days since their last use, the average and maximal frequency of
their use in the last year measured in days per month, their
estimated cumulative dose for last year, their average daily dose
last year, their highest daily dose last year and the duration
of regular use last year measured in months. Qualitative drug
screens were performed on the day of the examination by
means of urine samples for amphetamines, benzodiazepines,
cocaine, methadone, MDMA, and cannabis (enzyme-multiplied
immunoassay, von Minden GmbH). Moreover, hair samples
were randomly taken in one third of the participants (for
financial considerations) and analyzed for the substances,
MDMA, MDA, MDEA, amphetamine, methamphetamine, and
cannabinoids by the Institute of Legal Medicine at the University
of Cologne in order to verify the self-reported substance use.
In addition, a questionnaire regarding health behavior was used
in order to control for confounding variables such as alcohol
and cigarette use, sleep patterns, nutrition, participation in
sports, and subjective well-being (Fragebogen zur Erfassung des
Gesundheitsverhaltens; FEG; (Dlugosch and Krieger, 1995).
Neuropsychological Test Battery
The selection of tests in the present study is based on the results
of previous cross-sectional and longitudinal studies of MDMA
users, which identified alterations in the areas of working
memory, learning, memory, and frontal executive functions. For
a more detailed description, we refer the reader to our previous
study (Wagner et al., 2013). A German version of the Rey
Auditory Verbal Learning Test (AVLT) was used to assess verbal
declarative memory performance (Heubrock, 1992). The “Lern-
und Gedächtnistest” (LGT 3) (Bäumler, 1974) is a visual paired
association learning task. Figural visual recognition was assessed
by a subtest of the Lern- und Gedächtnistest (LGT; Bäumler,
1974), which is a classical paired associates learning task. Two
subtests of the German version of the Wechsler Intelligence
Test (WAIS) were used (Tewes, 1994). The Digit-Span-Test was
administered to assess the capacity of the working-memory,
and the Digit-Symbol-Test was used to assess the speed of
information processing. Moreover, the Stroop Task assessed
processing-speed and attention (Stroop, 1935; Bäumler, 1985),
and the Trail-making Test measured mental flexibility (Reitan,
1992). We also administered the Raven Standard Progressive
Matrices to assess non-verbal general intelligence (Raven et al.,
1998).
Statistical Analyses
Three groups of subjects were defined: those who had not used
any other illicit drugs apart from cannabis over the course of
the 2-year period (non-users); those who had used at least one
but not more than 49 ecstasy pills (moderate-users); and those
who had used more than 50 pills (heavy-users) over the course
of 2 years. In comparison to the first follow-up study, it was
possible to assess a group with more heavy MDMA use (see
group characteristics). Nevertheless, this sample did not include
such heavy use as compared to the other cross-sectional studies
mentioned. The group arrangement is based on other studies that
had similar or even greater classification ranges with regard to
moderate and heavy use (Fox et al., 2001; Reneman et al., 2001)
MDMA users and non-users were compared by means of a
one-way analysis of variance according to the following possible
confounding variables: age, general intelligence (Raven score),
number of days since last cannabis use, duration of regular
cannabis use before the initial assessment and duration of regular
cannabis use between the second and third assessments. The use
of cannabis was measured as the duration of regular use because
this has been suggested to have the greatest impact on cognitive
performance (Wagner et al., 2010).
In order to assess the participants’ health behavior, the
authors conducted a one-way analysis of variance of the
groups (0 pills, 1–49 pills, 50, or more pills) as independent
variables and as dependent variables the computed variables from
the questionnaire regarding their health behavior (Fragebogen
zur Erfassung des Gesundheitsverhaltens; FEG; (Dlugosch and
Krieger, 1995). This questionnairemeasures different dimensions
of the participants’ health behavior, including the subjects’
satisfaction with their diet, the frequency of their participation in
sporting activities (e.g., jogging, bicycling, hiking, walking), their
mean consumption of alcoholic drinks (e.g., beer, wine, liquors),
their mean drug use (e.g., painkillers, stimulants, tranquilizers,
sleeping pills), their sleeping problems and their feelings of
subjective well-being.
To evaluate whether the neurotoxic effect of MDMA was
affecting the cognitive performance of the participants over the
course of 2 years, we conducted three repeated measures analyses
of variance (ANOVA) for each separate cognitive domain with
the group (0 pills, 1–49 pills, 50 or more pills) as between-subject
factor and time of measurement and the cognitive variables
as within-subject factors. The first repeated measures ANOVA
addressed the subjects’ attention and information processing
speed (Trail-Making Test part A, Stroop Task parts A and
B, digit symbol test). The second repeated measures ANOVA
addressed the subjects’ episodic memory (AVLT indices, LGT
3 indices). The third repeated measures ANOVA addressed the
subjects’ frontal/executive functioning (Trail-Making Test part
B, Stroop Task part C, digit span test backwards). Furthermore,
we computed the effect size of all significant differences,
operationally defined as η2. All analyses were performed with
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IBM SPSS statistical software program version 21 (Chicago, IL,
USA).
RESULTS
Group Characteristics
Of the initial 149 subjects who participated in the first assessment,
96 subjects participated in the third assessment after 2 years.
Thirty-one subjects did not use any other illicit substance beside
cannabis over the course of the 2-year period (non-users). Fifty-
five subjects used more than 0.5 but fewer than 49 ecstasy pills
(M = 10.14; SD = 9.98; range: 0.5–45; mean occasion: 1.76;
SD = 1.45; range: 0–10). Ten subjects used more than 50 ecstasy
pills (M = 85.80; SD = 54.39; range: 51–228; mean occasion:
3.52; SD = 1.73; range: 2–6.5). On average the consumption of
MDMA declined in both groups in the second follow-up period.
We found for moderate-users (t1: M = 6.42; SD = 7.33; t2:
M = 3.71; SD = 5.3) and for heavy-users (t1: M = 51.90;
SD = 37.28; t2:M = 33.9; SD = 25.46).
A repeated measures ANOVA addressing the decline in
consumption of MDMA revealed a significant interaction effect
for group and time [F(2, 93) = 0.8654, p = 0.000].
The corresponding within-subject contrasts showed significant
changes in consumption of MDMA between time-point 2 (t1)
and time-point 3 (t2). With respect to the reported means in
parenthesis, these results indicate a significant decline inMDMA-
use in the heavy-user group between t1 and t2 (see also Figure 1).
For each group, gender distribution, mean age, mean duration
of cannabis use before the baseline, mean duration of cannabis
use between the baseline and the second assessment, mean days
since the last cannabis use at the third assessment, Raven score
and corresponding standard deviations are provided in Table 1.
The groups differed regarding the mean age, use of cocaine,
solvent/inhalants, and amphetamines. Therefore, these variables
beside amphetamine were entered as covariates into the analysis.
There was no difference in the use of hallucinogens and cannabis.
As expected, a high concomitant use of amphetamines in the
moderate- and heavy-user group was found (correlation MDMA
and amphetamine use: r = 0.304, p = 0.003). In addition, a
high concomitant use of cocaine in the moderate- and heavy-user
FIGURE 1 | Mean “MDMA-use” within follow-up period one and
follow-up period two. Error bars denote the standard error around the
mean. *Significant difference between time-point 2 (t1) and time-point 3 (t2).
group was also found (correlation MDMA and cocaine use:
r = 0.210, p = 0.04). The corresponding means and standard
deviations of the use of concomitant substances are provided in
Table 2. Urine screens of all participants that were included in the
analyses were free of amphetamines, benzodiazepines, cocaine,
methadone, and MDMA. Moreover, the hair samples that were
randomly taken and screened by, the Institute of Legal Medicine
at the University of Cologne confirmed the subjects’ self-reported
substance use in all cases except one (which was excluded from
the analyses).
Health Behavior
A one-way analysis of variance was conducted with respect to
the health behavior of the participants. There was no significant
difference between the groups regarding any of the variables. The
means, standard deviations, and significance levels are presented
in Table 3.
Performance Effects
This was a mixed ANOVA with group (three levels) as between-
subject factor and time (three levels) as within-subject factor.
The repeated measures ANOVA addressing attention and
information processing speed revealed no significant interaction
effect for group and time [F(12, 168.00) = 0.823, p = 0.627].
Mean test scores for each group as well as significance levels of
the corresponding tests of univariate test effects are provided in
Table 4.
The repeated measures ANOVA addressing episodic memory
revealed a marginal significant interaction effect for group and
time [F(32, 148.00) = 1.432, p = 0.080, η
2 = 0.236]. Significant
interaction between group and time were found regarding
univariate tests for the immediate recall test [F(4, 175.30) = 3.939,
p = 0.026, η2 = 0.060] and the delayed recall test [F(4, 177.883) =
3.996, p = 0.028, η2 = 0.059].
The corresponding within-subject contrasts showed
significant changes in performance between time point 1
(t0) and time point 2 (t1) [F(2, 89) = 4.323, p = 0.016], and
no significant changes between time point 2 (t1)and time point
3 (t2) [F(2, 89) = 0.021, p = 0.979] regarding the immediate
recall test. With respect to the reported means in Table 5,
these results indicate an increase in performance in immediate
recall for the non-user and moderate-user groups, with a
decline in performance in the heavy-user group between t0
and t1. However, the mean test scores indicate an increase in
performance in all groups between t1 and t2. Scores on the
immediate recall test for each group between t0 and t2 are also
represented graphically in Figure 2.
For the delayed recall test, the corresponding within-subject
contrasts showed significant changes in performance between
time points t0 and t2 [F(2, 89) = 5.048, p = 0.008]. No changes in
performance were found between time points t0 and t1 [F(2, 89) =
2.199, p = 0.117], nor between t1 and t2 [F(2, 89) = 1.004,
p = 0.370]. With respect to the reported means in Table 5,
these results indicate that the non-user and the moderate-user
groups increased in performance between t0 and t2, without an
increase in the heavy-user group. Mean test scores for each group
as well as significance levels of the corresponding univariate tests
Frontiers in Neuroscience | www.frontiersin.org 4 December 2015 | Volume 9 | Article 445
Wagner et al. Cognition in New MDMA Users
TABLE 1 | Group characteristics.
Female/Malee Aged Cannabis use at
baselinea,d
Cannabis use
within follow-upa,d
Days since last
cannabis useb,d
Raven scorec,d
Non-users 9/22 23.77 (±3.87) 46.09 (±34.79) 11.5 (±9.99) 2.0 (±7.48) 6.03(±3.80)
Moderate-users 21/34 21.87 (±3.78) 41.15 (±41.48) 16.71 (±21.78) 1.03 (±2.76) 7.78 (±6.68)
Heavy-users 3/7 26.70 (±7.54) 58.30 (±72.10) 10.80 (±14.41) 2.40 (±5.36) 11.10 (±6.15)
F-/P-value 830/660 6.08(2.93)/0.003 0.687(2.93)/0.506 1.070(2.93)/0.347 0.310(2.93)/0.735 2.92(2.93)/0.059
Frequencies of gender, mean age, mean duration of cannabis use, mean days since last cannabis use and mean Raven score for each users group. Standard Deviations are given in
parenthesis.
aRegular use is measured in months.
bMeasured at third assessment.
cMeasurement of general intelligence (lower score indicates better performance).
dComputed by means of a One-way ANOVA between non-users (0 pills), moderate-users (1–49 pills), and heavy-users (50 or more pills) of 3,4-Methylenedioxymethamphetamine
(MDMA).
eComputed by means of chi-square test.
TABLE 2 | Concomitant illicit substances use.
Cannabisa Cocainea Hallucinogensb Solvents/Inhalantsb Amphetaminesa
Non-users 39.77 (±53.67) 0.53 (±2.08) 0.0 (±0.0) 23.77 (±3.87) 3.24 (±7.68)
Moderate-users 74.17 (±130.69) 9.55 (±55.62) 0.50 (±2.57) 21.87 (±3.78) 19.59 (±28.49)
Heavy-users 72.34 (±78.23) 110.58 (±341.33) 0.50(±1.58) 26.70 (±7.54) 110.67 (±341.33)
F-/P-value 1.13 (2/93)/0.327 12.08 (2.93)/0.026 0.641(2.93)/0.529 4.62(2.93)/0.012 12.08(2.93)/0.000
Mean cannabis, cocaine, hallucinogens, solvents/inhalants, amphetamines use for each user group between the baseline assessment and the third assessment. Standard deviations
are given in parenthesis.
aCumulative use measured in grams.
bCumulative use measured in occasions from the baseline (t0) until the second assessment (t2).
TABLE 3 | Health behavior.
Satisfaction with diet* Exercisea** Alcohol useb** Medical treatmentc** Sleepd Subjective well-beinge*
Non-users 2.12 (±4.84) 15.51 (±2.15) 7.54 (1.52) 8.35 (±1.62) 6.45 (±2.21) 1.39 (±1.30)
Moderate-users 2.72 (±5.02) 14.87 (±3.29) 7.54 (1.75) 8.52 (±1.76) 7.18 (±2.68) 1.45 (±1.18)
Heavy-users 3.30 (±5.61) 14.09 (2.42) 8.00 (1.41) 9.40 (±3.33) 8.40 (±4.03) 1.20 (±1.81)
F-/P-value 0.251 (2.93)/0.818 0.515(2.92)/0.599 0.338(2.93)/0.976 1.12(2.93)/0.328 2.11(2.92)/0.127 0.168(2.93)/0.846
Means of the follow-up period between the first assessment and the second assessment. Standard Deviations are given in parenthesis. Computed by means of a One-way ANOVA
between non-users (0 pills), moderate-users (1–49 pills), and heavy-users (50 or more pills) of 3,4-Methylenedioxymethamphetamine (MDMA).
aFrequency of exercise.
bMean consumption of alcoholic drinks.
cFrequency of intake of different drugs.
dHours per night.
eGeneral satisfaction with one’s life.
*Measured by means of a 7-point likert scale (−3 = very dissatisfied; 3 = very satisfied). **Measured by means of a four-point likert scale (1 = never; 4 = daily) by adding all items
scores.
are provided in Table 5. Scores on the delayed recall test for
each group between t0 and t2 are also represented graphically in
Figure 3.
The last repeated measures ANOVA addressing
frontal/executive functioning also did not reveal a significant
interaction effectfor group and time [F(12, 168.00) = 0.823,
p = 0.627]. The mean test scores for each group as well as
significant levels of the corresponding tests of univariate test
effects are provided in Table 6. By entering amphetamines as a
covariate into the repeated measure ANOVA, the effects for the
LGT3-LOGO-Test do not remain marginally significant.
DISCUSSION
The current prospective study investigated the effect of MDMA
on cognitive performances in incipient MDMA users over the
course of a 2-year period. The results of the first follow-up
assessment showed significant deficits in MDMA users in visual
paired association learning after a period of 1 year (Wagner
et al., 2013). Based on those results it was hypothesized that
the sustained use of MDMA over a period of 2 years would
lead to further decline in cognitive performance, especially in
heavy MDMA users. The same cognitive test battery which
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TABLE 4 | Mean Neuropsychological Test Score for 3,4-methylenedioxymethamphetamine (MDMA) users and non-users related to attention and
information processing speed.
Test Non-users Moderate-users Heavy-users Sig η2
Mean (SD) (n = 31) Mean (SD) (n = 55) Mean (SD) (n = 10)
B AS 1 AS 2 B AS 1 AS 2 B AS 1 AS 2
TMT-A 25.76 (7.9) 23.30 (6.9) 21.17 (8.9) 27.61 (9.45) 22.60 (8.47) 20.31 (5.26) 25.03 (5.0) 25.39 (6.07) 22.58 (4.5) 0.256 0.029
ST-A 29.00 (7.5) 26.62 (4.7) 25.55 (3.2) 29.89 (8.77) 26.85 (4.20) 26.49 (4.58) 29.00 (4.4) 30.84 (12.0) 25.95 (2.9) 0.908 0.003
ST-B 44.33 (8.2) 42.65 (7.2) 41.46 (6.4) 45.44 (11.2) 42.11 (6.93) 40.31 (8.14) 48.20 (7.4) 46.57 (6.57) 45.00 (4.5) 0.739 0.009
DST 61.84 (8.8) 67.19 (9.5) 69.13 (8.8) 61.69 (11.6) 65.58 (11.8) 68.67 (12.0) 57.10 (9.5) 60.10 (10.1) 61.60 (9.5) 0.761 0.010
B, baseline measurement; AS, assessment; TMT-A, Trail-Making Test A; ST-A, Stroop Task A reading condition; ST-B, Stroop Task B color naming condition; DST, Digit Symbol Test.
TABLE 5 | Mean Neuropsychological Test Score for 3,4-methylenedioxymethamphetamine (MDMA) users and non-users related to episodic memory.
Test Non-users Moderate-users Heavy-users Sig.* η2
Mean (SD) (n = 31) Mean (SD) (n = 55) Mean (SD) (n = 10)
B AS 1 AS 2 B AS 1 AS 2 B AS 1 AS 2
RAVLT Aa 7.19 (2.02) 7.39 (2.39) 7.61 (2.06) 7.18 (2.00) 7.07 (1.87) 7.47 (2.19) 7.00 (2.36) 6.60 (1.17) 6.40 (1.43) 0.934 0.005
RAVLT Bb 6.35 (2.12) 6.42 (2.03) 6.16 (1.79) 6.36 (2.23) 6.22 (1.93) 6.24 (2.26) 5.10 (2.24) 5.20 (1.93) 5.60 (2.68) 0.967 0.003
RAVLT Cc 12.32 (2.18) 11.94 (2.62) 12.13 (2.32) 11.96 (2.42) 12.15 (2.77) 11.55 (2.96) 10.80 (2.35) 9.70 (3.09) 10.20 (3.43) 0.288 0.028
RAVLT Dd 1.23 (1.63) 1.84 (2.18) 1.55 (1.50) 1.42 (2.00) 1.13 (1.65) 2.38 (2.71) 1.30 (1.95) 2.38 (2.71) 2.00 (1.41) 0.136 0.039
RAVLT Ee 14.19 (1.78) 14.26 (0.97) 14.42 (1.03) 13.98 (1.39) 13.67 (1.65) 13.87 (1.55) 13.20 (1.87) 13.00 (1.94) 11.70 (3.20) 0.106 0.042
RAVLT Ff 4.39 (0.99) 4.06 (1.24) 3.97 (1.34) 4.33 (1.04) 4.22 (1.08) 4.22 (1.07) 4.70 (0.68) 4.60 (0.84) 4.60 (0.84) 0.773 0.010
LGT 3 logos Ag 12.90 (2.80) 12.35 (2.47) 14.81 (2.98) 11.51 (3.48) 11.76 (3.33) 14.07 (3.91) 12.90 (3.90) 9.70 (1.95) 12.10 (2.69) 0.026 0.060
LGT 3 logos Bh 11.58 (3.20) 12.00 (2.86) 13.87 (2.93) 10.84 (3.56) 11.13 (3.75) 13.35 (4.15) 12.40 (3.47) 10.00 (2.71) 10.50 (3.54) 0.028 0.059
B, baseline measurement; AS, assessment; SD, standard deviation. P-values refer to tests of univariate test effects of the corresponding repeated measures ANOVA. Significant *P-values
are given in bold.
aRey Auditory Verbal Learning Test (RAVLT) A: immediate recall.
bRAVLT B: total acquisition.
cRAVLT C: recall after interference.
dRAVLT D: loss after interference.
eRAVLT E: recognition performance.
fRAVLT F: repetitions required for learning.
gLern- und Gedächtnistest (LGT) 3 A: immediate recall.
hLGT 3 B: delayed recall.
was used during the first assessment, including tests of the
subject’s attention and information processing speed, memory,
working memory and executive functioning, were also used
during the second assessment. Out of the initial 149 subjects who
participated in the first assessment, 96 subjects participated in the
second assessment after 2 years. The analyzed data showed no
differences concerning possible confounding variables, including
the subjects’ cannabis use, alcohol use, and their current medical-
treatment, participation in sports, diet, satisfaction with sleep,
and feelings of subjective well-being. However, the groups did
differ with regard to the subjects’ mean age, their use of cocaine,
solvents, inhalants, and amphetamines, as well as differences
with regard to the subjects’ general intelligence. Therefore, these
variables were considered as possible confounding variables.
The repeated measures ANOVA addressing episodic memory
indicated a specific effect regarding paired association learning
and MDMA use. A marginally significant interaction effect of
group and time for both immediate and delayed recall memory
subtests from the Lern- und Gedächtnistest (LGT; Bäumler,
1974) was suggested. The analyzed data showed differences in
performance among the groups between the baseline and the
first assessment for the immediate recall memory test. Based
on these results, it seems that the non-user and moderate-user
groups increased in performance between the baseline and the
first assessment. Furthermore, it appears that the performance
of the heavy-user group decreased in the first follow-up period.
These results are in line with the already published findings from
the study of Wagner et al. (2013) that demonstrated a dose-
related neurotoxic effect of MDMA on visual paired associates
learning. However, it seems that with respect to the second
follow-up period, this effect no longer occurred. Based on the
results of the second follow-up assessment, it appears that the
performance of all groups improves with regard to the immediate
recall test after a period of 2 years. The findings of the current
study for the first follow-up period are congruent with previous
results from other investigations that found deficits in associative
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learning with poorer immediate and delayed recall abilities in
MDMA users compared to non-users (Daumann et al., 2005;
Montgomery et al., 2005; Quednow et al., 2006; Parrott, 2013a).
FIGURE 2 | Mean performances on the immediate recall test for time
points t0, t1, and t2 for the groups, non-users, moderate-users, and
heavy-users.
FIGURE 3 | Mean performances on the delayed recall test for time
points t0, t1, and t2 for the groups, non-users, moderate-users, and
heavy-users.
However, as already mentioned, the analyzed data showed a
similar improvement in performance for the immediate recall
test for all groups between the first assessment and the second
assessment. These results are consistent with the findings of
de Sola Llopis et al. (2008). In their study, they also found
an improvement in the performance of MDMA users after a
follow-up period of 2 years. However, the overall performance
of the MDMA users was still lower when compared to the
non-users. They postulated that the subjects’ improvement in
performance could be due to practice effects through their
repeated exposure to the test material. Therefore, it may also
be possible that the participants in the current study performed
better because they were better acquainted with the test material.
The use of parallel versions from neurocognitive tests could be a
solution to prevent such practice effects in future studies. Perhaps
another explanation for the improvement in performance in
the heavy-user group could be a decrease in their MDMA use
between the first and second assessments (see Figure 1). Similar
results were found in other longitudinal studies: Heavy-users
improved their performance on an immediate recall test in
which the average use of MDMA had decreased between the
first and second assessments (Thomasius et al., 2003; Gouzoulis-
Mayfrank et al., 2005). A last explanation for the marginal
significant effect of MDMA-use between the groups could be
that the non-user group also could have been impaired in
cognitive performance before participating in this study due
to their little experience with MDMA. Because even a small
cumulative dose of MDMA, is associated with a decline in
cognitive performance (Schilt et al., 2007). For the future, it
would be interesting to add a group without any drug experience
to rule out preexisting cognitive impairments due to MDMA-use
in the control-group.
With respect to performance on the delayed recall test, it
seems that the groups changed in performance between the
baseline assessment and the second assessment. It appears that an
improvement in performance occurred among the non-users and
moderate-users, but not in the heavy-user group. More precisely,
a performance decline in heavy-users took place between baseline
and the first assessment, with no further deterioration in
performance between the first and the second assessments. This
could indicate a dose-related neurotoxic effect of MDMA within
the first follow-up period—as was already found in the study of
TABLE 6 | Mean Neuropsychological Test Score for 3,4-methylenedioxymethamphetamine (MDMA) users and non-users related to frontal/executive
functioning.
Test Non-users Moderate-users Heavy-users Sig. η2
Mean (SD) (n = 31) Mean (SD) (n = 55) Mean (SD) (n = 10)
B AS 1 AS 2 B AS 1 AS 2 B AS 1 AS 2
TMT-B 66.87 (23.8) 51.63 (18.4) 54.03 (17.5) 66.87 (26.2) 54.95 (18.6) 53.71 (17.7) 79.19 (22.8) 63.63 (25.3) 63.90 (10.9) 0.855 0.006
ST-C 73.52 (13.8) 67.78 (14.1) 66.66 (11.6) 72.95 (14.7) 66.58 (14.6) 65.28 (10.9) 83.91 (17.8) 74.28 (15.8) 71.40 (10.8) 0.981 0.002
DSB 8.19 (1.97) 7.81 (2.32) 9.81 (4.69) 7.80 (2.27) 8.49 (2.60) 8.62 (2.10) 7.10 (2.64) 7.20 (2.04) 8.00 (2.16) 0.073 0.049
B, baseline measurement; AS, assessment; SD, standard deviation. P-values refer to the significance levels of univariate test effects of the corresponding repeated measures ANOVA.
TMT-B, Trail-Making Test B; ST-C, Stroop Task C interference condition; DSB, Digit Symbol backwards Test; SD, standard deviation.
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Wagner et al. (2013)—but not for the second-follow-up period.
Therefore, it seems that continuing MDMA, use did not lead
to further decrease in performance on the delayed recall test
after 2 years, a result which corresponds with the previous
findings of Gouzoulis-Mayfrank et al. (2005). Furthermore, no
significant changes in performance within the 2-year follow-
up period were found, results which are similar to the findings
of Brown et al. (2010). Brown and colleagues also established
significant effects on association learning tasks with regard to
MDMAusers and non-users, but no differences concerning other
memory tasks. However, it has not been establishedwhether these
other measures of cognitive performance may also decrease over
time with prolonged use of MDMA over the subject’s lifetime.
Therefore, longitudinal studies including follow-up assessments
over a period of several years are needed.
As already established in our analysis of the data from
the first follow-up period (Wagner et al., 2013), a significant
intercorrelation was found between the subjects’ use of MDMA
and amphetamine in the second follow-up period. It still remains
unclear whether or not the impairments in visual pair associates
learning can be ascribed to the subjects’ use of MDMA alone or
whether it is also due to their concomitant use of amphetamine.
However, in their study, Gouzoulis-Mayfrank et al. (2003)
attributed the subjects’ performance on the same immediate
and delayed recall test to their use of MDMA rather than to
their polydrug-use of MDMA and amphetamine. More research
concerning memory deficits in humans with respect to the
neurotoxic effects of amphetamine are needed. Furthermore,
there was also a significant intercorrelation between the subjects’
use of MDMA and cocaine. However, the confounding effect
of cocaine did not fully account for the differences between
the groups on the visual paired association task. Even after
excluding cocaine as a covariate, the results on the visual paired
association task remained marginal significant. Even though
dose-related neurotoxic effects of MDMA have been established,
among incipient MDMA users in their first year of regular use,
it seems that this effect no longer exists or at least diminishes
after a second year of MDMA use. In this respect, the findings
of the current study could be interpreted as contradicting the
MDMA-related memory decline in continuing users. Otherwise,
a further decrease in performance within the second year,
would be expected. Another explanation could be that the
neurotoxic potential of MDMA displays its effect on memory
at the beginning of regular MDMA use in novice users without
an exponential deterioration through continued use. In a recent
study, Taurah et al. (2013), argued that prolonged use of MDMA
is a weak predictor for memory deficits. Instead, they argue
that it is a combination of MDMA use with other drugs that
seems crucial for memory deficits in recent and past MDMA
users (Taurah et al., 2013). However, most studies reveal that
prolonged lifetime use of MDMA leads to memory deficits in
MDMA users (Parrott et al., 2002; Parrott, 2013a). Moreover,
the performance of MDMA users gets worse when they are
confronted with supraspan tasks, where their memory systems
become overloaded beyond their normal capacities (Parrott,
2013a). In this respect, the LGT 3 is such a supraspan task
(Bäumler, 1974). This test has been shown to be sensitive in
detecting performance deficits in MDMA users (Gouzoulis-
Mayfrank et al., 2003).
The recent literature shows that impairment in MDMA users
can be found in almost all cognitive domains (Parrott, 2013b).
In their study, Quednow et al. (2006) found deficits in verbal
declarative memory in MDMA users compared to non-users.
The subjects’ verbal declarative memory was assessed with the
Rey Auditory Verbal Learning Test (RAVLT; Heubrock, 1992),
which was likewise used in our current study as an assessment
tool. However, as compared to our study, Quednow et al.
(2006) looked at a group of former MDMA users with a longer
lifetime and higher cumulative use of MDMA. Regarding to
the longer lifetime use and higher cumulative use of MDMA,
it might be possible that the performance of MDMA users
on the declarative memory task in the current study may
continue to decline if they continue to use MDMA in the
following years.
The findings on the tests of executive functioning are
consistent with the previous study of Halpern et al. (2011).
They also found no differences on tests of executive functioning
(Trail-Making Test A and B), except with the digit span
test backwards from the WAIS 3. Although MDMA users
showed impairments on the digit span test backwards, significant
differences were only established between the non-user and
moderate-user groups, and not between the heavy-user and non-
user groups. This is inconsistent with the dose-related neurotoxic
effect hypothesis of MDMA. Moreover, no differences between
the groups were found in performance on the Stroop Tasks,
a result which corresponds with our findings. In summary,
the results of the current study indicate a MDMA-related
performance decrease in heavy MDMA users on a visual paired
association task. A reason for the performance decrease in
heavy MDMA users on visual paired association tasks could
be hippocampal dysfunction, because the hippocampus plays
a crucial role in learning processes and memory, and it is
particularly vulnerable to the neurotoxic effects of MDMA
(Hatzidimitriou et al., 1999; Daumann et al., 2005; Brown et al.,
2010; Pergola and Suchan, 2013). Interestingly, in a recent
prospective fMRI study by Becker et al. (2013), continuing
MDMA users showed, in contrast to abstinent MDMA users, a
decrease in encoding-related activity in the left parahippocampus
during an association memory task. However, no differences
in performance on this task were found between the groups.
This suggests that MDMA users are still able to perform
in a normal range despite an MDMA-specific dysfunction of
the parahippocampus. One possible explanation could be that
MDMA users do not want to believe that their results on
memory performance tests could be negatively affected by
their MDMA use. Consequently, they may try harder to reach
normal results and thereby compensate for the dysfunction of
their parahippocampus. In a recent functional near-infrared
spectroscopy (fNIRS) study by Roberts, Wetherell, Fisk and
Montgomery (Roberts et al., 2015) they found also no behavioral
performance differences on a high mental workload task between
MDMA-users and non-users. However, in comparison to non-
users, MDMA-users showed an aberrant neuronal functioning
in the dorsolateral prefrontal cortex (DLPFC), suggesting that
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MDMA-users have neurological impairments in these networks.
Also in Electroencephalography (EEG) studies, neuronal changes
in MDMA-users are found in the absence of a decrease in
behavioral performances (Burgess et al., 2011; Roberts et al.,
2013). Therefore, it seems that performance on cognitive
tasks between MDMA-users and non-users alone are not
sensitive enough to measure cognitive impairments induced
by MDMA-use.
Despite the empirical evidence found in animal studies for the
neurotoxic effect of MDMA in the hippocampus and other brain
regions, the underlying molecular mechanisms have not been
fully clarified. There are different factors that seem to contribute
to the neurotoxic effect of MDMA. For example, heightened
ambient temperature influences themetabolites ofMDMAwhich
are associated with the induction of 5-HT toxicity (Moon et al.,
2008; Capela et al., 2009) and decreases the activity of tryptophan
hydroxylase (TPH), an enzyme that is required for the synthesis
of 5-HT (Moon et al., 2008). Oxidative stress induced through
MDMA administration leads to an increase in reactive oxygen
species (ROS) and decreases the antioxidant defense of cells,
which leads to cell damage and mitochondrial dysfunction
(Moon et al., 2008; Capela et al., 2009). As a consequence of
an increased monoamine oxidase metabolism of monoamine
neurotransmitters (dopamine, noradrenaline, adrenaline, and
serotonin), more toxic metabolites can be found in cells. This
subsequently leads to cell damage.
However, the underlying mechanism of MDMA, which can
cause neurodegeneration and changes in the serotonin system,
is still difficult to identify in humans (Green et al., 2012).
Most evidence regarding the underlying molecular mechanisms
came from studies using laboratory species. This creates
difficulties in translating such information to human MDMA
users (Green et al., 2012). Furthermore, there are findings which
are inconsistent with the neurodegeneration hypothesis. For
example, serotonergic fibers have been found to remain in rats
even after MDMA administration and indeed to recover from
the neurotoxic effects of MDMA (Hatzidimitriou et al., 1999;
Kish et al., 2010; Biezonski and Meyer, 2011). With respect
to the empirical evidence of the neurodegenerating effects of
MDMA on human users, it is therefore important to consider
that serotonergic deficits are not necessarily the result of axonal
damage. Therefore, Biezonski and Meyer (2011) noted that
“MDMA can certainly be considered as neurotoxic in terms of
causing serotonergic dysfunction.”
It should be noted that the current study is not free of
certain methodological limitations, as we have already discussed
in our previous paper. Like other open-trial studies, this study
was not experimental, and, therefore, it provides no causal
interpretation of the effect of MDMA on brain regions which
are associated with specific cognitive performance. This study
began with a large sample of 149 subjects. However, only 96
subjects remained for the second follow-up assessment, and
most of these were non-users or moderate-users. Therefore,
the subjects were unevenly distributed over the groups, with a
small sample size of 10 subjects in the heavy-user group. In
addition, the remaining 10 participants in the heavy-users group
might be actually highly motivated and that might constitute a
bias in terms of performance and might partially explain the
results found in the present study. Furthermore, in the recent
study MDMA-users consumed cannabis almost twice as much
as non-users. Even though the concomitant use of cannabis
did not differ significantly between the groups, a possible
confound of cannabis cannot be completely ruled out. Some
investigators have suggested a possible neuroprotective effect
of Tetrahydrocannabinol (THC) against MDMA neurotoxicity
in laboratory animals (Tourino et al., 2010; Lopez-Rodriguez
et al., 2014). In this regard, cannabis might be preventing
a performance decline in moderate-users but not in heavy-
users due to their excessive use of MDMA. In a fMRI-
study of Daumann et al. (2003) pure MDMA-users presented
lower activations of different brain regions during a working-
memory task in comparison to polyvalent- and non-users,
suggesting a neuroprotective effect of cannabis against MDMA
neurotoxicity.
Furthermore, in the recent study a significant difference
between the groups in their use of cocaine was found.
Although, no interaction effect of MDMA and cocaine was
found on cognitive functioning, a confounding effect of cocaine
cannot completely ruled out, too. Investigators found cognitive
impairments on different cognitive domains in cocaine-users
(Potvin et al., 2014). Thus, in the recent study, the impairments
in visual pair associates learning cannot only be attributed
to MDMA alone but also to the concomitant use of cocaine
and cannabis, which is a common limitation to prospective
MDMA-studies. Further limitations, which are common to all
longitudinal, MDMA research in humans have already been
intensively discussed. For these, we refer the reader to our already
published study (Wagner et al., 2013).
In conclusion, the already published findings of the first
follow-up period seem to be consistent with the findings of the
current study. In this study, we found an MDMA-related decline
in memory performance on a visual paired association test in
the first follow-up period in heavy MDMA users, suggesting
an MDMA-related dysfunction of the hippocampal regions.
However, no further deterioration was observed in the second
follow-up period, that could be due tomethodological limitations
of the recent study, which are inherent to open-trial studies and
mentioned below.
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